Vijaya Diagnostic Centre Ltd Q3 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Published 5 Aug 2026 | Healthcare Services | Market Cap: ₹14.3K Cr
The company targets a 15% compound annual growth rate (CAGR) over the next 3 years. The company targets a 15% CAGR growth over the next 3 years, driven primarily by ~13% volume growth and 2% realization growth, resulting in mid-teens overall revenue growth.
From Vijaya Diagnostic Centre Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,504
Market Cap
₹14.3K Cr
P/E Ratio
82.7
How does Vijaya Diagnostic Centre Ltd rank in Healthcare Services?
Compare Vijaya Diagnostic Centre Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.
Vijaya Diagnostic Centre Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹219 Cr, net profit ₹48 Cr.
Full financials →📊 Revenue & Sales Performance
- →The company targets a 15% compound annual growth rate (CAGR) over the next 3 years.
- →Expected volume growth is around 13% per year, with the remaining revenue growth attributed to value or realization growth of approximately 2%.
- →Growth outlook includes significant hub expansion: 12 hubs planned over 1.5 years, including new geographies like Bangalore, Pune, and Kolkata.
- →New hubs are expected to take about 1 year to achieve EBITDA breakeven.
- →Market share gains are expected in core geographies (Andhra Pradesh and Telangana) due to brand strength, dense network, and advanced technology.
- →Wellness segment growth remains strong, contributing about 14% to the top line, with potential seasonal Q4 benefits.
- →The company's conservative guidance aims to overachieve actual growth, with potential upside from new hub additions and market expansion.
📈 Profitability & Margins
- →The company targets a 15% CAGR growth over the next 3 years, driven primarily by ~13% volume growth and 2% realization growth, resulting in mid-teens overall revenue growth.
- →Plans to add around 12-14 new hub centers across FY '25 and FY '26 to fuel growth, including expansion into new geographies like Bengaluru, Pune, and Kolkata.
- →EBITDA margins expected to remain around 40%, with a possible 1-2% short-term dip when multiple hubs open simultaneously; EBITDA breakeven in new hubs anticipated within 1 year.
- →Pre-IndAS EBITDA margins were around 33.5%, currently 40% under IndAS due to rent treatment, indicating underlying margin strength.
- →PAT margins currently near 21%, with an expected ~1% positive impact adjusting for pre-IndAS.
- →Operating leverage seen in 3-4% range typically, but near term growth investments and GST impact (~0.3%) might moderate margin expansion.
- →Long term margin expansion expected post stabilization and densification of new hubs and markets.
🏗️ Capital Expenditure Plans
- →The company has budgeted INR 200 crores capex for commissioning 12 new hub centers over FY '25 and '26.
- →This INR 200 crores capex includes renovation and addition of extra MRI at Kurnool.
- →Additional two hub centers in Andhra Pradesh and Telangana are planned, with leases under finalization, expected by Q3 FY '26.
- →Capex plans remain materially unchanged despite new hubs and PET-CT machine in Tirupathi.
- →PET-CT at Tirupathi is on a pay-per-use model, thus not part of capex.
- →Focus on strategic expansion across Bangalore, Pune, Kolkata, and adjacent geographies.
- →Investments continue in IT systems and CRM to enhance customer experience and operational efficiency.
- →Capex strategy supports ability to rapidly expand and densify network beyond core geographies.
💰 Fundraising & Capital Structure
- →There is no mention of any current or future fundraising through debt or equity in the transcript.
- →The company is maintaining a strong cash position with approximately INR 200 crores in surplus cash and treasury balance.
- →Capex plans for the next 1 to 1.5 years, including 12-14 new hub centers and a renovation project, are planned within an INR 200 crore budget funded internally.
- →The company is focusing on strategic expansion and capital allocation without indicating any need for additional external funding.
- →PET-CT equipment was acquired on a pay-per-use model to optimize capital allocation, indicating a preference for internal capital efficiency rather than new debt or equity.
- →Overall, the company appears well-capitalized to meet its growth plans without requiring fundraising at this time.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Vijaya Diagnostic Centre Ltd Q3 FY25 results?
The company targets a 15% compound annual growth rate (CAGR) over the next 3 years. The company targets a 15% CAGR growth over the next 3 years, driven primarily by ~13% volume growth and 2% realization growth, resulting in mid-teens overall revenue growth.
What is Vijaya Diagnostic Centre Ltd share price analysis?
Vijaya Diagnostic Centre Ltd currently shows a neutral. The stock trades at a P/E of 82.7 with a market cap of ₹14,313 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vijaya Diagnostic Centre Ltd planning capital expenditure?
The company has budgeted INR 200 crores capex for commissioning 12 new hub centers over FY '25 and '26.
Keep Vijaya Diagnostic Centre Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.